Correlations of EGFR mutations and increases in EGFR and HER2 copy number to gefitinib response in a retrospective analysis of lung cancer patients (Q33290653)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Correlations of EGFR mutations and increases in EGFR and HER2 copy number to gefitinib response in a retrospective analysis of lung cancer patients	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

25 July 2017

Correlations of EGFR mutations and increases in EGFR and HER2 copy number to gefitinib response in a retrospective analysis of lung cancer patients (English)

1 reference

Europe PubMed Central

25 July 2017

1 reference

based on heuristic

inferred from title

object named as

Trevor J Pugh

1

0 references

author name string

Gwyn Bebb

2

1 reference

Europe PubMed Central

25 July 2017

Lorena Barclay

3

1 reference

Europe PubMed Central

25 July 2017

Margaret Sutcliffe

4

1 reference

Europe PubMed Central

25 July 2017

John Fee

5

1 reference

Europe PubMed Central

25 July 2017

Chris Salski

6

1 reference

Europe PubMed Central

25 July 2017

Robert O'Connor

7

1 reference

Europe PubMed Central

25 July 2017

Cheryl Ho

8

1 reference

Europe PubMed Central

25 July 2017

Nevin Murray

9

1 reference

Europe PubMed Central

25 July 2017

Barbara Melosky

10

1 reference

Europe PubMed Central

25 July 2017

John English

11

1 reference

Europe PubMed Central

25 July 2017

Jeurgen Vielkind

12

1 reference

Europe PubMed Central

25 July 2017

Doug Horsman

13

1 reference

Europe PubMed Central

25 July 2017

Janessa J Laskin

14

1 reference

Europe PubMed Central

25 July 2017

Marco A Marra

15

1 reference

Europe PubMed Central

25 July 2017

language of work or name

0 references

publication date

13 July 2007

1 reference

Europe PubMed Central

25 July 2017

1 reference

Europe PubMed Central

25 July 2017

7

1 reference

Europe PubMed Central

25 July 2017

128

1 reference

Europe PubMed Central

25 July 2017

https://scigraph.springernature.com/pub.10.1186/1471-2407-7-128

0 references

Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1952070

21 June 2018

EGFR inhibitors: what have we learned from the treatment of lung cancer?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1952070

21 June 2018

Activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor are associated with improved survival in gefitinib-treated chemorefractory lung adenocarcinomas.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1952070

21 June 2018

Erlotinib in lung cancer - molecular and clinical predictors of outcome

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1952070

21 June 2018

Asian ethnicity and adenocarcinoma histology continues to predict response to gefitinib in patients treated for advanced non-small cell carcinoma of the lung in North America

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1952070

21 June 2018

Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1952070

21 June 2018

Mutations in the tyrosine kinase domain of the epidermal growth factor receptor in non-small cell lung cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1952070

21 June 2018

Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1952070

21 June 2018

Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1952070

21 June 2018

A small molecule-kinase interaction map for clinical kinase inhibitors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1952070

21 June 2018

Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1952070

21 June 2018

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1952070

21 June 2018

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1952070

21 June 2018

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1952070

21 June 2018

Epidermal growth factor receptor: a promising target in solid tumours

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1952070

21 June 2018

Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1952070

21 June 2018

Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1952070

21 June 2018

The human genome browser at UCSC

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1952070

21 June 2018

dbSNP: the NCBI database of genetic variation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1952070

21 June 2018

Primer3 on the WWW for general users and for biologist programmers

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1952070

21 June 2018

Consed: a graphical tool for sequence finishing

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1952070

21 June 2018

Base-calling of automated sequencer traces using phred. II. Error probabilities

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1952070

21 June 2018

Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-7-128

21 January 2018

Increased HER2 gene copy number is associated with response to gefitinib therapy in epidermal growth factor receptor-positive non-small-cell lung cancer patients

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-7-128

21 January 2018

Synchronous overexpression of epidermal growth factor receptor and HER2-neu protein is a predictor of poor outcome in patients with stage I non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-7-128

21 January 2018

Selecting patients for epidermal growth factor receptor inhibitor treatment: A FISH story or a tale of mutations?

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-7-128

21 January 2018

Unraveling the mystery of prognostic and predictive factors in epidermal growth factor receptor therapy

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-7-128

21 January 2018

Assessing EGFR mutations

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-7-128

21 January 2018

Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-7-128

21 January 2018

High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-7-128

21 January 2018

Absence of epidermal growth factor receptor exon 18-21 mutation in hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-7-128

21 January 2018

Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-7-128

21 January 2018

EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-7-128

21 January 2018

Cellular targets of gefitinib

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1952070

31 October 2018

Epidermal growth factor receptor and HER2-neu mRNA expression in non-small cell lung cancer Is correlated with survival.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1952070

31 October 2018

Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria

1 reference

https://pubmed.ncbi.nlm.nih.gov/17626639

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1186/1471-2407-7-128

1 reference

Europe PubMed Central

25 July 2017

Dimensions Publication ID

0 references

1 reference

Europe PubMed Central

25 July 2017

1 reference

Europe PubMed Central

25 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33290653&oldid=1966786057"